June 13, 2025

RSV Vaccine Approved for Younger Adults

The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.

Conexiant

June 13, 2025

Riva Returns!

Luigi Mondello explains why the time is right to reignite Chromatography’s much-missed “scientific retreat”

The Analytical Scientist

June 13, 2025

Endoscopic Sinus Surgery Speeds Recovery

A retrospective study comparing endoscopic and traditional open sinus surgery for chronic rhinosinusitis with nasal polyps found shorter operative times, fewer complications, and improved outcomes associated with the endoscopic technique.

Conexiant

June 12, 2025

Gene Variants Linked to CPPD Risk

A large genetic study in U.S. veterans has identified ENPP1 and RNF144B as genes associated with calcium pyrophosphate deposition disease, suggesting potential for targeted treatment approaches.

Conexiant

June 12, 2025

Vegetarian Diet Linked to Lower Cancer Incidence

A large North American cohort study found that vegetarian diets were associated with lower risks of several site-specific cancers, including colorectal, stomach, breast, prostate, and lymphoproliferative cancers.

Conexiant

June 11, 2025

8-Week Oral Therapy Approved for Acute HCV

The FDA has approved Mavyret for the treatment of acute hepatitis C, offering physicians a pangenotypic, 8-week oral regimen for early intervention.

Conexiant

June 10, 2025

FDA Pledges Week-Long Drug Reviews

New leadership outlines accelerated approval processes, AI integration, and food additive restrictions to address the chronic disease epidemic

Conexiant

June 09, 2025

NIH Staff Challenge Leadership's Research Policies

Federal scientists release formal dissent declaration opposing administration's grant terminations and policy changes affecting biomedical research.

Conexiant

June 06, 2025

RSV or COVID: Which Strains the Heart?

A study of 32,960 hospitalizations finds 10.9% of patients with RSV experienced acute cardiovascular events, with significantly higher adjusted odds than boosted and unboosted COVID-19 cases.

Conexiant